News | Heart Valve Technology | July 22, 2015

Direct Flow Medical Announces FDA Approval to Broaden SALUS U.S. Trial

Expansion brings high-risk surgical patients, randomization against Medtronic CoreValve into trial

Direct Flow Medical, Transcatheter Aortic Valve System, SALUS Trial, FDA

July 22, 2015 Direct Flow Medical Inc. received Investigational Device Exemption (IDE) approval from the U.S. Food and Drug Administration (FDA) in April to broaden its SALUS Trial. The expansion includes the addition of high-risk patients and randomization against a commercial device, the Medtronic CoreValve. 

The SALUS Trial is a prospective, randomized, multi-center, core lab adjudicated U.S. clinical trial, evaluating the Direct Flow Medical Transcatheter Aortic Valve System. The primary endpoint of the trial is a composite of all-cause mortality and disabling stroke at 12 months. Principal investigators for the SALUS Trial are Murat Tuzcu M.D., vice chairman of the Department of Cardiology, Cleveland Clinic; and Patrick McCarthy, M.D., director of the Bluhm Cardiovascular Institute and chief of cardiac surgery, Northwestern Memorial Hospital.

The expansion of the SALUS Trial includes the following changes:

  • Treatment of high surgical risk patients and continued treatment of extreme risk patients;
  • 2:1 randomization to Medtronic CoreValve;
  • 912 subject pivotal cohort;
  • Up to 45 sites in the U.S.; and
  • Registries for non-femoral access points and type 2 and 3 bicuspid valves.

 

The repositionable and retrievable Direct Flow Medical system is designed to treat patients with severe aortic stenosis who are at high or extreme surgical risk by replacing the native aortic valve, while minimizing the degree and frequency of aortic regurgitation (AR). AR has been shown to be a strong predictor of long-term mortality. The system is designed to address this clinical concern by sealing the annulus and enabling complete assessment of hemodynamic performance with repositioning of the valve after full deployment. The system is designed to avoid rapid pacing of the heart during deployment and post-dilatation following placement, minimizing the risk of hemodynamic instability for patients.

"We have been working closely with the FDA since the early development of the Direct Flow Medical technology and it has been a collaborative effort with the FDA which has led to an expansion of the SALUS trial. The technology has shown outstanding performance in clinical trials and commercial settings, significantly reducing the risk of aortic regurgitation with excellent survival. We look forward to expanding the clinical use to additional centers in the U.S. and continuing to obtain the same strong outcomes in the pivotal trial," said Tuzcu.

An earlier feasibility phase of the SALUS Trial conducted in 2013 evaluated the system in 30 patients. Thirty-day outcomes demonstrated a survival rate of 97 percen, with 100 percent of patients experiencing mild or less aortic regurgitation. Results also showed low procedural complications, no incidence of stroke and a three percent rate of permanent pacing. The mean aortic gradient decreased from 44.5 mmHg to 12.7 mmHg at 30 days. The previous protocol of the SALUS Trial enrolled more than 100 extreme risk patients in a non-randomized fashion and will continue to be followed independently.

The Direct Flow Medical system received the CE Mark in January 2013 and is currently available commercially in Europe.

For more information: www.directflowmedical.com

Related Content

Boston Scientific, Edwards Lifesciences Agree To Global Litigation Settlement
News | Heart Valve Technology | January 15, 2019
Boston Scientific Corp. and Edwards Lifesciences Corp. announced that the companies have reached an agreement to settle...
The implantation of a MitraClip is guided under live transesophageal echo (TEE). This image shows the operator moving the open clip into position and engaging the mitral valve leaflets. The clip appears as a arrowhead shape in the ultrasound with the leaflets coming off each side. Photo from a MitraClip procedure at the University of Colorado Hospital. Dr. Dominick Wiktor. The TEE is from a Philips Epiq system.

The implantation of a MitraClip is guided under live transesophageal echo (TEE). This image shows the operator moving the open clip into position and engaging the mitral valve leaflets. The clip appears as an arrowhead shape in the ultrasound with the leaflets coming off each side. Photo from a MitraClip procedure at the University of Colorado Hospital.

Feature | Heart Valve Technology | January 14, 2019 | Allen Atchley, M.D., FACC, The Chattanooga Heart Institute
Mitral regurgitation (MR) is one of the most common types of heart valve diseases in the United States, affecting app
JC Medical Announces First U.S. Treatment With J-Valve TAVR Device
News | Heart Valve Technology | January 07, 2019
January 7, 2019 — JC Medical announced the successful treatment of the first U.S.
Edwards' Sapien 3 Ultra Transcatheter Heart Valve Receives FDA Approval
Technology | Heart Valve Technology | January 02, 2019
Edwards Lifesciences Corp. announced that the Sapien 3 Ultra system has received U.S. Food and Drug Administration (FDA...
Boston Scientific Prevails in U.S. Edwards Lifesciences Litigation
Feature | Heart Valve Technology | December 12, 2018
A jury in the U.S. District Court for the District of Delaware determined Dec. 11 that the Boston Scientific U.S....
First TriCinch Coil Tricuspid Repair Systems Implanted in U.S.
News | Heart Valve Technology | November 06, 2018
4Tech Inc. initiated its U.S. Early Feasibility Study of the TriCinich Coil System following U.S. Food and Drug...
Valve Replacement Volume Key to Successful Patient Outcomes
News | Heart Valve Technology | November 02, 2018
Hospitals that routinely perform a heart valve replacement procedure requiring open heart surgery are more likely to...
Prosthetic Valve Mismatches Common in TAVR Procedures
News | Heart Valve Technology | October 03, 2018
A high number of patients in a study who underwent transcatheter aortic valve replacement (TAVR) experienced severe and...
Local Anesthesia Safe and Effective for Intermediate- and High-Risk TAVR Patients
News | Heart Valve Technology | September 28, 2018
The first randomized study to compare general versus local anesthesia during transcatheter aortic valve replacement (...
Overlay Init